Revenue cycle · AI insurance-denial appeals for patients and providers
Claimable
Claimable is a physician-led company whose AI builds evidence-based appeals of health-insurance denials, from medical-necessity and step-therapy denials to formulary exceptions, then mails and faxes them to the insurer for patients, providers and health systems.
Strong fit
- Patients denied specialty drugs such as Humira, Dupixent, Mounjaro, Zepbound, Wegovy, Vyepti or IVIG
- Practices in rheumatology, asthma, eczema, migraine and weight management that see repeat medical-necessity denials
- Health systems that want patient-side appeals added to their existing EHR and RCM workflow
Weak fit
- Denials caused by administrative errors or missing information
- Treatments outside the 85-plus medications Claimable supports
- Hospital billing teams that need high-volume claim-level denial management
Bottom line
Claimable is a strong option for patients and practices fighting medical-necessity and step-therapy denials on specialty drugs, with a flat consumer price and reported win rates near 80%. Its coverage is limited to the conditions and treatments it has built evidence for. Hospitals working large volumes of coding and billing denials will need a claim-level revenue-cycle tool alongside it.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Warris Bokhari, a former NHS physician who later worked at GE, Apple Health, Anthem and Amazon, co-founded Claimable in 2023 with Alicia Graham and Zach Veigulis, a former chief data scientist at the Department of Veterans Affairs. The company launched its appeal service in October 2024 and closed a seed round that year backed by Walkabout Ventures and Humanrace Capital. Bloomberg reported in April 2026 that Claimable had raised $10 million from investors including Mark Cuban.
A patient uploads the denial notice and insurance details, answers questions about the condition and what the treatment means to them, and Claimable generates an appeal drawn from clinical research, insurance law, policy documents and prior appeals. The patient reviews the letter, and Claimable sends it to the insurer by fax and first-class mail. Business Insider reported that Claimable also sends a copy to every regulator with oversight of the insurer.
Claimable says 80% of its appeals succeed and most are resolved in 10 days or less. Claimable told Bloomberg in April 2026 that about three in four users saw their denials reversed. In one case on Claimable's provider page, Premera denied infliximab three times over nine months; a 23-page appeal was approved in 48 hours.
For providers and health systems, Claimable handles medical-necessity and step-therapy denials, connects to existing EHR and RCM systems, and says it saves more than 15 hours of staff time per appeal. Bloomberg Businessweek reported four signed drugmaker deals as of April 2026.
Patients on Trustpilot rate Claimable 4.7 from 33 reviews. "Created a streamlined appeal letter that approved my appeal within 24 hour business hours," wrote one reviewer in September 2026. Another, Yvonne Beers, wrote: "With Claimable, I was able to submit my appeal without any input from my doctor and received a positive decision from my insurance carrier in less than 24 hours." The complaints are about pace and process. "It took a long time and added steps to get the claim to be seen and finally approved," one July 2026 reviewer wrote. "I wish the emails to check in would have an option other than approved or denied."
Adonis fits hospital revenue-cycle teams that want AI agents to research denials and prepare claim-level appeals, and Sift Healthcare fits health systems that want to predict denials before claims go out.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Adonis | 7.8 | 7.6 |
| Claimable | 7.4 | 7.2 |
| Sift Healthcare | 7.1 | 6.8 |
| Janus Health | 6.9 | 6.9 |
| Cofactor AI | 6.7 | 6.6 |
Pricing
| Item | Detail |
|---|---|
| Model | Claimable charges patients a flat fee per appeal. Many medications are free for qualifying patients through its network of support partners, and patients who cannot afford the fee are pointed to the nonprofit Coverage Fund. |
| What usually drives cost | For patients, whether the medication is covered by a support partner; for providers and health systems, the contract terms Claimable sets with each organization. |
| What to ask before you buy | Whether Claimable supports the drug and denial type, whether a support partner covers the fee, and the terms of each provider or health-system contract. |
| Note | Claimable charges no success fees. TIME (February 2026) and PYMNTS (April 2026) reported a patient fee of about $50 per appeal; Claimable's site lists $39.95 plus shipping. |
| Published pricing | A flat $39.95 plus shipping per appeal for patients who do not qualify for free access. Provider and health-system pricing is not published. |
Leadership
- Warris Bokhari, MDCo-founder and CEO
- Zach VeigulisCo-founder and CAIO
- Alicia GrahamCo-founder
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.